Cambridge-based CN Bio has expanded its contract research services by integrating PhysioMimix computational modelling tools with existing organ-on-chip platforms, creating a comprehensive approach to absorption, distribution, metabolism and excretion (ADME) profiling for pharmaceutical development.

EpiCypher has launched CUTANA® Fiber-seq, a multiomic genomics platform that simultaneously captures genomic and epigenomic information through single long-read sequencing assays. The Durham, North Carolina-based company announced the technology on 3 September 2025, marking a significant development in molecular genomics capabilities.

A new service from Aptamer Group promises to reduce biomarker discovery timelines from years to months, reshaping how pharmaceutical and diagnostic companies approach disease marker identification. The platform combines cutting-edge synthetic biology with advanced proteomics to deliver both validated biomarkers and functional binding tools simultaneously.

FUJIFILM Biosciences has introduced BalanCD HEK293 Perfusion A Medium, the first commercially available cell culture solution specifically optimised for HEK293 cells in perfusion processes. The medium targets gene therapy applications, enabling continuous production of adeno-associated virus (AAV) and lentivirus (LV) vectors with enhanced consistency and scalability.

Vapourtec has launched the Peptide-Builder, a benchtop solid-phase peptide synthesis (SPPS) system designed to streamline peptide production in research and clinical laboratories. The automated platform combines compact design with high-throughput capabilities, addressing space constraints whilst maintaining synthesis performance.